Joseph Schocken was appointed Director of Omeros Corp. As of November 6, 2026, Omeros Corp has reported 2 leadership change filings to the SEC under Item 5.02 of Form 8-K, from August 13, 2026 to October 30, 2026, naming 2 appointments (Form 8-K, August 13, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Omeros Corp? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Omeros Corp reported changes in 2 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-08-13 to 2026-10-30. They name 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as Omeros Corp files it.
Also on the record for Omeros Corp
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| July 29, 2026 | Stake report, Schedule 13G/A, by BlackRock, Inc. | 8.2% of the class | 5%+ stakes | Source |
| April 23, 2026 | Stake report, Schedule 13G/A, by INGALLS & SNYDER LLC | 4.8% of the class | 5%+ stakes | Source |
| March 27, 2026 | Stake report, Schedule 13G/A, by The Vanguard Group | — | 5%+ stakes | Source |
| January 30, 2026 | Stake report, Schedule 13G, by The Vanguard Group | 5.66% of the class | 5%+ stakes | Source |
| October 31, 2025 | Stake report, Schedule 13G/A, by The Vanguard Group | 4.91% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Omeros Corp now and the warning signs.
Free to see. No signup.
Keep reading
More on Omeros Corp and the records around it.
Omeros Corp elsewhere on the record
Companies that share a holder
- BlackRock, Inc. also filed stake reports on 1596 other companies: AvePoint, Inc. (Nov 2026), BIOMARIN PHARMACEUTICAL INC (Nov 2026), MSG RANGERS CORP (Nov 2026)
- The Vanguard Group also filed stake reports on 2384 other companies: BellRing Brands, Inc. (Sep 2026), CAL-MAINE FOODS INC (Sep 2026), FTAI Aviation Ltd. (Sep 2026)
Watch Omeros Corp
Get an email when Omeros Corp files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Omeros Corp?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Omeros Corp: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Omeros Corp covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
7 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-10-30 | Reported | not named in the filing | 8-K, 2026-10-30 | ||
| 2026-08-13 | In | Director | 8-K, 2026-08-13 | ||
| 2026-08-13 | In | 8-K, 2026-08-13 |
Who leads Omeros Corp, as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Director: Joseph Schocken, appointed (filed 2026-08-13).
New leaders reset buying decisions — get the Full Report on Omeros Corp: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Director at Omeros Corp, with the record behind each one.
Find candidates like Director at Omeros CorpEvery change, in the filing's words
Reported
The Performance Award is allocated equally across four tranches, with vesting on a tranche-by-tranche basis subject to (i) achievement of stock price hurdles of $25.00, $30.00, $35.00 and $40.00 per share, calculated based on the aggregate volume-weighted average price of the Company's common stock over a period consisting of 30 consecutive trading days, taken as a single measurement period, at any point during the five-year term of the award, and (ii) satisfaction of a time-based condition, under which 25% of each tranche of the Performance Award will become eligible for vesting on the first
- On October 28, 2026, the Compensation Committee (the "Committee") of the Board of Directors of Omeros Corporation (the "Company") granted a performance-based stock option award (the "Performance Award") to Gregory A. Demopulos, M.D., the Company's Chief Executive Officer, under the Company's Amended and Restated Omnibus Incentive Compensation Plan (the "Plan").
- The Performance Award consists of an option to purchase up to 500,000 shares of the Company's common stock that will vest only upon satisfaction of both future stock-price performance and continued-service vesting conditions, subject to the provisions described below.
- No portion of the Performance Award was vested, and no shares were issued, on the grant date.
- The exercise price of the Performance Award is $17.88 per share, which was the closing price of the Company's common stock on the date of grant.
- The stock price hurdles represent appreciation of approximately 40%, 68%, 96% and 124%, respectively, above the grant-date closing price.
- Any shares acquired upon exercise of the vested portion of the Performance Award must be purchased at the exercise price in accordance with the Plan and award agreement.
- The Performance Award will expire on October 28, 2031.
Appointed: Joseph Schocken, Director
On August 12, 2026, the Board of Directors of Omeros Corporation (the "Company" or "we"), upon recommendation of the Nominating and Governance Committee of the Board of Directors, increased the number of its directors to nine and appointed Joseph Schocken as a director, effective immediately.
Appointed: Joseph Schocken
The Board of Directors also appointed Mr. Schocken to the Audit Committee of the Board of Directors.
- Mr. Schocken's initial term will expire at our 2027 annual meeting of shareholders or his earlier resignation or removal.
- Mr. Schocken, 79, is a private investor and the founder and president of Tranceka Capital, LLC.
- Mr. Schocken founded Seattle-based investment bank Broadmark Capital LLC in 1987.
- In 2010, Mr. Schocken co-founded and served as chief executive officer of the entities that became Broadmark Realty Capital, Inc. (NYSE) until its merger in 2019.
- He served as its post-merger chairman from 2019 through 2021.
- He currently serves as chairman of Taqtile, Inc., a digital work assistance platform.
- Mr. Schocken has long been involved in politics and economic policy on a national level.
- He is recognized as one of the driving forces behind the JOBS Act, has testified on economic policy before committees of the U.S. House and Senate, and was a Presidential appointee to the National Advisory Council on Innovation and Entrepreneurship.
- He received his MBA from Harvard University and his BA in history from the University of Washington.
- Pursuant to our non-employee director compensation policy, Mr. Schocken was granted a stock option to purchase 30,000 shares of our common stock on the date of his appointment.
- Mr. Schocken will be indemnified by the Company pursuant to the terms of our standard form of director indemnification agreement.
Tools for this story
Each opens in a new tab, filled in for Omeros Corp. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.